Abstract: A process for preparing the drug-loaded cyanoacrylate nanoparticles is described. The cyanoacrylate nanoparticles which effectively deliver biological and therapeutic agents are synthesized by miniemulsion polymerization with surfactant, pluronic F127 or F68. Before initiation of polymerization, active agents with particularly highly hydrophobicity are dissolved in cyanoacrylate monomer. Compared with the drug-loaded polyalkylcyanoacrylate nanoparticles produced by emulsion polymerization, those produced by miniemulsion polymerization possess higher loading and encapsulation efficiencies. While the content of dissolved agents increases, furthermore, the loading and encapsulation efficiencies increase concurrently.
Abstract: Provided is affinity chromatography carrier for an immunoglobulin that simultaneously has high immunoglobulin-binding capability and chemical stability and that can be produced at low cost. An immunoglobulin-binding protein in which an amino acid substitution for not only maximizing the number of lysine residues on the protein surface of helix 3 and its periphery but also minimizing the number of lysine residues present on the protein surfaces of helix 1 and helix 2 as immunoglobulin-binding regions and/or an amino acid substitution for eliminating an aspartic acid-proline sequence have (has) been carried out, or a multimer thereof, is used as an affinity ligand for an affinity chromatography carrier.
Abstract: The present invention concerns a process for producing compositions that are rich in secretory IgA (S-IgA) by fractionating milk containing S-IgA. Such compositions may be used in particular for treating and/or preventing infections and/or inflammation of the mucosal surfaces, e.g. the gastro-intestinal tract, urogenital tract, respiratory tract, nasal cavity or oral cavity, treating and/or preventing obesity and related diseases, or treating and/or preventing food allergies in subjects in need of such treatment. Briefly stated, the current invention provides a process for producing milk fractions rich in secretory Immunoglobulin A, using one or more microporous membrane filtration steps. A preferred protocol of the present process involves de-fatting, micro-filtration and ultrafiltration-concentration through a number of diafiltration cycles.
Type:
Grant
Filed:
May 11, 2009
Date of Patent:
March 11, 2014
Assignee:
W. Health L.P.
Inventors:
Charles Maria Hubert Hensgens, Nanda De Groot
Abstract: An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3 CDRS in SEQ ID NO: 9.
Abstract: Semisolid mucoadhesive formulations for vaginal application, with improved technical and organoleptic characteristics, which contain at least two bioadhesive gelling polymers and an active ingredient, useful in the prevention and/or treatment of various pathologies and disorders in human beings or animals.
Type:
Grant
Filed:
July 16, 2004
Date of Patent:
March 4, 2014
Assignee:
ITF Research Pharma, S.L.U.
Inventors:
Álvaro Acebrón Fernández, Ana Campuzano Garcia, Rosa Maria Hernández Martin, Manuela Igatúa Olaechea, José Luis Pedraz Muñoz, Alicia Rodriguez Gascón
Abstract: Soy products or compositions are treated with a food grade iodate compound or a cystine compound to reduce levels of methanethiol, sulfites and sulfite free-radicals, sulfate free radicals and other free radicals generated from sulfite free radicals in the soy products or compositions by 1% to 95%.
Type:
Grant
Filed:
September 7, 2006
Date of Patent:
March 4, 2014
Assignee:
University of Kentucky Research Foundation
Abstract: The present invention relates to devices, articles, coatings, and methods for controlled active agent release and/or for providing a hemocompatible surface. More specifically, the present invention relates to copolymer compositions and devices, articles, and methods regarding the same for controlled active agent release. In an embodiment, the present invention includes a copolymer composition. The copolymer composition can include a copolymer and an active agent. In an embodiment, the copolymer includes an effective portion of a monomeric unit including a polar moiety. The active agent can be polar. The active agent can be charged. The active agent can be non-polar. In an embodiment, the copolymer composition includes a random copolymer. In an embodiment, the random copolymer includes butyl methacrylate-co-acrylamido-methyl-propane sulfonate copolymer, which can provide reduced platelet adhesion.
Type:
Grant
Filed:
July 26, 2006
Date of Patent:
March 4, 2014
Assignee:
Surmodics, Inc.
Inventors:
Timothy M. Kloke, Robert W. Hergenrother, Laurie R. Lawin
Abstract: Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and light chain variable region (“VK”). The FW regions may contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. The human or humanized VH framework regions may comprise one or more of the following residues: a valine at position 24 of FW1, a glycine at position 49 of FW2, and an asparagine at position 73 of FW3, numbered according to Kabat. Further provided are pharmaceutical and immunotherapeutic compositions, and methods using anti-CD22 antibodies that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases in humans, including B cell malignancies, autoimmune disease, GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder.
Abstract: A composition includes calcium sulfate hemihydrate, stearic acid, an accelerant, and a mixing solution. The composition can be injected, e.g., through a needle, and is capable of setting, e.g., in vivo, in a relatively short period of time to a relatively high hardness.
Abstract: The present invention relates to DEK protein compositions (e.g., antibodies, small molecule inhibitors, siRNAs) and methods of using the same. In particular, the present invention provides compositions and methods for treating autoimmune disease (e.g., juvenile rheumatoid arthritis, lupus, etc.) and for inhibiting inflammation (e.g., associated with autoimmune disease) and cellular chemotaxis (e.g., of neutrophils, NK cells and T cells). The present invention further provides a diagnostic marker (e.g., DEK antigen) for autoimmune disease.
Type:
Grant
Filed:
October 16, 2006
Date of Patent:
February 18, 2014
Assignee:
The Regents of the University of Michigan
Inventors:
David M. Markovitz, Nirit Mor-Vaknin, Michael Khodadoust, Barbara S. Adams
Abstract: The present invention provides a method for purifying a protein to remove impurities from a mixture liquid containing a desired protein and the impurities, comprising the step of performing filtration using a porous membrane having a graft chain on a pore surface and an anion-exchange group fixed to the graft chain.
Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agent compositions and formulations administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Type:
Grant
Filed:
May 26, 2009
Date of Patent:
February 11, 2014
Assignees:
Otonomy, Inc., The Regents of the University of California
Inventors:
Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
Abstract: The invention provides an article having a mesoporous silicate matrix, such as a particle, having one or more pores; and one or more releasable caps obstructing one or more of the pores for delivery of one or more agents to plant cells or other chlorophyll containing cells, or fungi.
Type:
Grant
Filed:
April 19, 2007
Date of Patent:
February 11, 2014
Assignee:
Iowa State University Research Foundation, Inc.
Inventors:
Francois Jean George Torney, Kan Wang, Victor Shang-Yi Lin, Brian G. Trewyn, Supratim Giri
Abstract: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
Type:
Grant
Filed:
March 21, 2012
Date of Patent:
January 28, 2014
Assignee:
The Regents of The University of Michigan
Inventors:
Yang Liu, Pan Zheng, Guo-Yun Chen, Xincheng Zheng, Xi Cheng, Steve Kunkel
Abstract: The current invention reports a method for concentrating an immunoglobulin solution by tangential flow filtration wherein the transmembrane pressure and the cross-flow are variable.
Type:
Grant
Filed:
July 15, 2008
Date of Patent:
January 21, 2014
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
Abstract: Cereal ?(1-3) ?(1-4) glucan is used as a film or coating agent to produce clear, edible, biodegradable, delivery, lubricating, and protecting agents. Cereal ?(1-3) ?(1-4) glucans are distinctive polymers of glucose differentiated from other polymers by not only their source but also their physicochemical properties. The ?(1-3) ?(1-4) forms a matrix to sequester other materials, such as pharmaceutical, medical and therapeutic agents, flavors, fragrances. The technology has applications to essential oils and non-aqueous materials that are rendered deliverable by the ?(1-3) ?(1-4) glucan. The ?(1-3) ?(1-4) glucan films described may be consumed whereby they dissolve in the mouth in a controlled manner and may be used for the delivery of pharmaceutical, medical or confectionery products.
Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
Abstract: The invention includes methods of isolating a multi-subunit protein which binds to an antigen-bearing moiety. The methods comprise generating a phage display library comprising a plurality of virus vectors.
Type:
Grant
Filed:
March 26, 2010
Date of Patent:
January 7, 2014
Assignee:
The Trustees of the University of Pennsylvania
Abstract: A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals.
Abstract: The present invention provides the method of obtaining IgA and IgM antibodies from chicken egg whites. The method involves separating chicken egg whites into two fractions which contain IgA and IgM antibodies exclusively. This separation method consists of raising the volume of the egg whites using purified water, lowering the pH of said volume, filtering the IgM fraction from said volume, precipitating the IgA fraction from the remaining volume, dialyzing the IgA fraction and drying the IgA and IgM fractions.